All stock lists
Nuveen New Jersey Quality Municipal Income Fund (New York Stock Exchange:NXJ)
US · Delayed Price · Currency is USD
Financial Services · Asset Management
$12.41+$0.02 (+0.16%)
Market cap
$512M
Insider Score
Health Score
Analyst consensus
Listed since
Sep 12, 2002
Website
Insider Score
––Not scored
NXJ Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Strong
From NXJ’s reported statements · Q1 2025 (trailing 12 months)
Profitability20 / 20
Keeps a healthy share of every dollar it sells.
- Revenue
- $18.6M
- Net income
- $3.7M
- Net margin
- 19.8%
Leverage20 / 20
Little or no net debt.
- Total debt
- $0
- Cash
- $200K
- Net debt / EBITDA
- -0.01x
Liquidity0 / 20
Owes more within a year than it holds to pay it.
- Current assets
- $200K
- Current liabilities
- $3.9M
- Current ratio
- 0.05
Cash generation20 / 20
The business funds itself from operations.
- Operating cash flow
- $27.4M
- Free cash flow
- $27.4M
- FCF margin
- 147.7%
Dilution & runway20 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 41.2M
- Share growth (1y)
- -0.6%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
NXJ Income Statement
| Fiscal Period | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Feb 28, 2025 | Nov 30, 2024 | Aug 31, 2024 | May 31, 2024 | Feb 28, 2023 | Nov 30, 2022 |
| Revenue | -$181.32 K | -$181.32 K | $9.47 M | $9.47 M | $9.02 M | $9.02 K |
| Revenue Growth (YoY) | -102.01 % | -2110.34 % | 104704.74 % | 104704.74 % | -3.14 % | -99.90 % |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $9.01 M | $0.00 |
| Gross Profit | -$181.32 K | -$181.32 K | $9.47 M | $9.47 M | $9.02 K | $9.02 K |
| SG&A Expense | $61.33 K | $61.33 K | $1.49 M | $1.49 M | $1.43 M | $1.43 K |
| R&D Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expenses | $61.33 K | $61.33 K | $1.49 M | $1.49 M | $1.43 M | $5.45 K |
| Operating Income | -$242.65 K | -$242.65 K | $7.98 M | $7.98 M | $7.59 M | $7.59 K |
| Pretax Income | -$1.47 M | -$1.47 M | $3.30 M | $3.31 M | $631.44 | $631.44 |
| Tax Provision | $626.00 | $626.00 | $0.00 | $1.12 K | -$630.81 K | -$9.90 M |
| Net Income | -$1.47 M | -$1.47 M | $3.30 M | $3.30 M | $631.44 | $631.44 |
| EPS (Basic) | -$0.04 | -$0.04 | $0.08 | $0.08 | $0.00 | $0.00 |
| EPS (Diluted) | -$0.04 | -$0.04 | $0.08 | $0.08 | $0.00 | $0.00 |
| Shares Outstanding | 41.23 M | 41.23 M | 41.23 M | 41.23 M | 41.48 M | 41.48 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.